Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 68.3%

Neg 0% Neu 68.3% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.